SeekingAlpha · Aug 19, 2026
Travere Therapeutics: Valuation Suggests A Buy
Travere Therapeutics is rated Buy, with a DCF-based fair value of ~$81 per share, implying 27% upside. Click here to read more about the TVTX stock.
TV
NASDAQ · TVTX
Travere Therapeutics, Inc.
Healthcare · Biotechnology
$52.13
Up+$0.09 (+0.16%)
Updated Oct 12, 2026, 1:05 AM
SID Score
5.7/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 3.13B
- P/E ratio
- -35.27
- Dividend yield
- 0.00%
- 52-week range
- $22.59 – $68.73
- Volume
- 1.17M
- Avg. volume
- 1.89M
Price performance · TVTX
TVTX price history
1M range · 0 trading sessions · Daily adjusted prices
TVTX does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest TVTX news
The latest Smart Investors Daily articles mentioning TVTX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
TVTX research
Overview
Company profile and research snapshot.
Company profile
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $35.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 24, 2026 | Guggenheim | Buy | — |
| Sep 22, 2026 | Wedbush | Outperform | — |
| Sep 22, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 10, 2026 | Evercore ISI Group | Outperform | — |
| Aug 6, 2026 | Wedbush | Outperform | — |
News briefing
No generated briefing is available yet.
Benzinga · Jul 30, 2026
Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $62
Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $56 to $62.
ChartMill · Jul 28, 2026
Travere Therapeutics (NASDAQ:TVTX) Earns Perfect Ratings in Breakout Setup Screen
Travere Therapeutics (TVTX) scores perfect 10/10 on technical and setup ratings, forming a bull flag pattern near resistance—ideal breakout candidate.
ChartMill · Jul 25, 2026
Travere Therapeutics (NASDAQ:TVTX): High Growth Momentum Stock with Breakout Setup
A stock screening method identifies breakout candidates with strong earnings momentum and technical setups. Travere Therapeutics (TVTX) scores high with a High Growth Momentum Rating of 6, perfect Technical Rating 10, and Setup Rating 8.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
